Form 4: Myomo Director Heather Getz Receives Significant RSU Grant

Myomo, Inc. Director Heather C. Getz was granted 29,720 Restricted Stock Units (RSUs) on June 11, 2025, as part of the company's 2018 Stock Option and Incentive Plan.

Summary

• Heather C. Getz, a Director of Myomo, Inc. (MYO), acquired 29,720 shares of Common Stock on June 11, 2025.
• This acquisition represents a grant of Restricted Stock Units (RSUs) under the Issuer's 2018 Stock Option and Incentive Plan.
• The RSUs were granted at a price of $0 per share, indicating a non-cash equity award.
• Following this transaction, Heather C. Getz beneficially owns a total of 41,754 shares of Common Stock.
• The granted RSUs are scheduled to vest in four equal quarterly installments, with the first vesting occurring on September 11, 2025.

Sentiment

Score: 6

Explanation: The grant of RSUs to a director is a routine compensation event, generally positive for aligning interests but not indicative of significant operational news. The slight future dilution from vesting is a minor negative, leading to a neutral to slightly positive sentiment.

Positives

• The grant of Restricted Stock Units (RSUs) to a director aligns their financial interests directly with the long-term performance and shareholder value of Myomo, Inc.
• This equity award serves as a retention mechanism, indicating continued commitment and incentivizing the director to contribute to the company's success.

Negatives

• The future vesting of these RSUs will result in a slight dilution of existing shares as new shares are issued from the company's equity plan.

Future Outlook

The granted Restricted Stock Units (RSUs) will begin vesting in four equal quarterly installments starting September 11, 2025, which will lead to the issuance of shares over time.

Industry Context

This Form 4 filing details a routine insider transaction involving equity compensation for a director, which is a common practice across publicly traded companies, particularly in the medical device and technology sectors. Such grants are standard components of compensation packages designed to align the interests of board members with those of shareholders.

Comparison to Industry Standards

• Granting Restricted Stock Units (RSUs) to directors is a widely accepted and common practice in publicly traded companies across various industries, including medical technology, as a form of non-cash compensation.
• The specified vesting schedule of four equal quarterly installments is a typical structure for RSU grants, commonly employed to incentivize long-term commitment and retention of key board members.
• The grant price of $0 is standard for RSU awards, as they represent a right to receive shares upon meeting specific vesting conditions, rather than an option to purchase at a set price.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholder value, potentially leading to better long-term decision-making. However, the future vesting and issuance of shares will result in a minor dilution of existing shares.
• Employees: No direct impact on employees is mentioned in this filing.

Next Steps

• The 29,720 Restricted Stock Units (RSUs) granted to Heather C. Getz will begin vesting in four equal quarterly installments starting September 11, 2025.

Key Dates

Keywords

Myomo, MYO, Form 4, SEC Filing, Restricted Stock Units, RSU Grant, Insider Transaction, Director Compensation, Equity Compensation, Beneficial Ownership